[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-446540-105":59,"doc-detail-446540-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","annex-1-manufacture-of-sterile-products","Annex 1 - Manufacture of Sterile Products","","Annex 1 provides general guidance for manufacturing sterile products, applying Quality Risk Management principles to prevent microbial, particulate, and pyrogen contamination in the final product. It outlines scope across sterile product types, sizes, processes, and technologies, including automated and manual systems. The annex emphasizes facility, equipment, and process optimization with GMP-aligned qualification and validation, supported by appropriate technologies. It also explains personnel qualification and risk-based management, clarifying that sterility assurance cannot rely on monitoring or testing alone.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/annex-1-manufacture-of-sterile-products/446540/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/annex-1-manufacture-of-sterile-products/446540.png","ImageObject",300,407,{"name":92,"@type":93},"Rainbow Cat","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of Annex 1 for sterile product manufacturing?","Question",{"text":112,"@type":113},"It provides general guidance for manufacturing sterile products using Quality Risk Management principles to prevent microbial, particulate, and pyrogen contamination in the final product.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which key areas must be considered to minimize contamination risks?",{"text":117,"@type":113},"Facility, equipment and process design optimized, qualified and validated; use of appropriate technologies for additional protection; and personnel qualifications, training, and suitable knowledge to manage sterile manufacturing activities.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is relying exclusively on monitoring or testing not sufficient for sterility assurance?",{"text":121,"@type":113},"Because the annex states that exclusively monitoring or testing does not give assurance of sterility; sterility risk must be controlled proactively through design, procedures, and monitoring as an ongoing confirmation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},446540,1791467020,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962090769181,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","1 Annex 1 : Manufacture of Sterile Products 2  \n3 Document map  \nSection Number  \n1. Scope  \n2. Principle  \n3. Pharmaceutical Quality System (PQS)  \n4. Premises  \n5. Equipment  \n6. Utilities  \n7. Personnel  \n8. Production and specific technologies  \n9. Viable and non-viable environmental and process monitoring  \n10. Quality control (QC)  \n11. Glossary  \nGeneral overview  \nIncludes additional areas (other than sterile products) where the general principles of the annex can be applied.  \nGeneral principles as applied to the manufacture of sterile products.  \nHighlights the specific requirements of the PQS when applied to sterile products.  \nGeneral guidance regarding the specific needs for premises design and also guidance on the qualification of premises including the use of Barrier Technology.  \nGeneral guidance on the design and operation of equipment.  \nGuidance with regards to the special requirements of utilities such as water, gas and vacuum.  \nGuidance on the requirements for specific training, knowledge and skills. Also gives guidance to the qualification of personnel.  \nDiscusses the approaches to be taken with regards to aseptic and terminal sterilization processes. Discusses approaches to sterilization of products, equipment and packaging components. Also discusses different technologies such aslyophilization and Form-Fill-Seal where specific requirements apply.  \nThis section differs from guidance given in section 4 in that the guidance here applies to ongoing routine monitoring with regards to the design of systems and setting of action limits alert levels and reviewing trend data.  \nThe section also gives guidance on the requirements ofAseptic Process Simulation (APS) .  \nGives guidance on some of the specific Quality Control requirements relating to sterile products.  \nExplanation of specific terminology.  \n4 5  \n6 1 Scope 7  \n8 The manufacture of sterile products covers a wide range of sterile product types (active substance, 9 sterile excipient, primary packaging material and finished dosage form), packed sizes (single unit to 10 multiple units), processes (from highly automated systems to manual processes) and technologies (e.g. 11 biotechnology, classical small molecule manufacturing and closed systems) . This Annex provides 12 general guidance that should be used for the manufacture of all sterile products using the principles of 13 Quality Risk Management (QRM), to ensure that microbial, particulate and pyrogen contamination is 14 prevented in the final product.  \n15  \n16 QRM applies to this document in its entirety and will not be referred to in specific paragraphs. Where 17 specific limits or frequencies are written, these should be considered as a minimum requirement. They 18 are stated due to regulatory historical experience of issues that have previously been identified and 19 have impacted the safety of patients.  \n20  \n21 The intent of the Annex is to provide guidance for the manufacture of sterile products. However, 22 some of the principles and guidance, such as contamination control strategy, design of premises, 23 cleanroom classification, qualification, monitoring and personnel gowning, may be used to support 24 the manufacture of other products that are not intended to be sterile such as certain liquids, creams, 25 ointments and low bioburden biological intermediates but where the control and reduction of 26 microbial, particulate and pyrogen contamination is considered important. Where a manufacturer 27 elects to apply guidance herein to non-sterile products, the manufacturer should clearly document 28 which principles have been applied and acknowledge that compliance with those principles should be 29 demonstrated.  \n30  \n31 2 Principle 32  \n33 2.1 The manufacture of sterile products is subject to special requirements in order to minimize risks of 34 microbial, particulate and pyrogen contamination. The following key areas should be considered:  \n35  \n36 i. Facility, equipment and process des","cbCaienNkZyjYobx","https://ap.wps.com/l/cbCaienNkZyjYobx","pdf",373551,52,"English","# Annex 1 : Manufacture of Sterile Products\n## Section 1 Scope\n## Section 2 Principle\n## Pharmaceutical Quality System (PQS)\n## Premises\n## Equipment\n## Utilities\n## Personnel\n## Production and specific technologies\n## Environmental and process monitoring\n## Quality control (QC)\n## Glossary","[{\"question\":\"What is the purpose of Annex 1 for sterile product manufacturing?\",\"answer\":\"It provides general guidance for manufacturing sterile products using Quality Risk Management principles to prevent microbial, particulate, and pyrogen contamination in the final product.\"},{\"question\":\"Which key areas must be considered to minimize contamination risks?\",\"answer\":\"Facility, equipment and process design optimized, qualified and validated; use of appropriate technologies for additional protection; and personnel qualifications, training, and suitable knowledge to manage sterile manufacturing activities.\"},{\"question\":\"Why is relying exclusively on monitoring or testing not sufficient for sterility assurance?\",\"answer\":\"Because the annex states that exclusively monitoring or testing does not give assurance of sterility; sterility risk must be controlled proactively through design, procedures, and monitoring as an ongoing confirmation.\"}]","Annex 1 - Manufacture of Sterile Products | PDF",1790715865,131]